Cargando…
Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis
A resazurin-based cell viability assay was developed for phenotypic screening of the LOPAC 1280 ‘library of pharmacologically active compounds’ against bloodstream forms of Trypanosoma brucei in vitro identifying 33 compounds with EC(50) values <1 μM. Counter-screening vs. normal diploid human fi...
Autores principales: | Jones, Deuan C., Hallyburton, Irene, Stojanovski, Laste, Read, Kevin D., Frearson, Julie A., Fairlamb, Alan H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025325/ https://www.ncbi.nlm.nih.gov/pubmed/20696141 http://dx.doi.org/10.1016/j.bcp.2010.07.038 |
Ejemplares similares
-
Lead Optimization of a Pyrazole
Sulfonamide Series
of Trypanosoma bruceiN-Myristoyltransferase Inhibitors: Identification and Evaluation
of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human
African Trypanosomiasis
por: Brand, Stephen, et al.
Publicado: (2014) -
Optimisation of the Anti-Trypanosoma brucei Activity of the Opioid Agonist U50488
por: Smith, Victoria C, et al.
Publicado: (2011) -
Development
of a 2,4-Diaminothiazole Series for the
Treatment of Human African Trypanosomiasis Highlights the Importance
of Static–Cidal Screening of Analogues
por: Cleghorn, Laura A. T., et al.
Publicado: (2023) -
The Design and Synthesis of
Potent and Selective Inhibitors
of Trypanosoma brucei Glycogen Synthase
Kinase 3 for the Treatment of Human African Trypanosomiasis
por: Urich, Robert, et al.
Publicado: (2014) -
Chemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosome
por: Jones, Deuan C, et al.
Publicado: (2012)